Mission
To ensure that our therapies have their greatest impact by always focusing on the patient, and following the science to run impactful and high-quality clinical development.
Pipeline
Linsitinib is an oral therapy being developed for thyroid eye disease (TED) that will ease the treatment burden for patients, caregivers, and physicians.
Leadership
We have an experienced team of executives, drug developers, and scientific advisors whose deep expertise and dedication keep them driving for solutions.
News
- Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
- Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease
- Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference